BioCentury | Nov 8, 2019
Clinical News

Cirius plots path forward for NASH candidate despite missed primary in Phase IIb

Cirius believes the results of a Phase IIb study could portend future clinical success for its next-generation insulin sensitizer to treat NASH, despite the compound’s failure to reach statistical significance in the trial’s primary analysis....
BioCentury | Sep 11, 2019
Company News

Sept. 10 Company Quick Takes: Lexicon, Sanofi part ways on diabetes drug; plus Mesoblast-Gruenenthal, Mateon-WideTrial, Intra-Cellular

Sanofi to pay Lexicon $260M as Zynquista ends Sanofi (NASDAQ:SNY) will pay Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) $208 million up front plus $52 million over the next 12 months as part of the companies’ agreement to...
BioCentury | Nov 2, 2018
Clinical News

Cirius NASH candidate improves liver enzymes in Phase IIb

...enzymes Status: Interim Phase IIb data Milestone: Additional Phase IIb data (2H19) Brian Moy MSDC-0602, MSDC-0602K Cirius Therapeutics Inc. Mitochondrial pyruvate carrier 1 (MPC1) (BRP44L)...
BioCentury | Jul 20, 2018
Company News

Tasly gets Chinese rights to two cell therapies from Mesoblast

Tasly Pharmaceutical Co. Ltd. (Shanghai:600535) received exclusive, Chinese rights to develop and commercialize mesenchymal precursor cell candidates MPC-150-IM and MPC-25-IC from Mesoblast Ltd. (ASX:MSB; NASDAQ:MESO). Mesoblast will receive a $40 million upfront payment comprising a...
BioCentury | Jun 30, 2018

Eyes on launches

The annual summer slowdown isn’t restricted to just the stock market this year, as the clinical catalyst calendar also appears to be on holiday in 3Q18. Buysiders are therefore turning their attention to a spate...
BioCentury | Mar 16, 2018
Emerging Company Profile

Cirius safety

...also bind two targets in the mitochondrial target of thiazolidinediones (mTOT) complex -- mitochondrial pyruvate carrier 1 (MPC1; BRP44L...
...are expected in mid-2019. MSDC-0602K is the only disclosed NASH program in the clinic targeting MPC1...
...COMPANY PROFILE Cirius Therapeutics Inc., Kalamazoo, Mich. Technology: Second-generation thiazolidinedione (TZD) that inhibits mitochondrial pyruvate carrier 1 (MPC1; BRP44L...
BioCentury | Apr 13, 2017
Clinical News

MPC-150-IM: Ph III ongoing

Mesoblast said an independent DMC recommended continuation of the double-blind, sham-controlled, U.S. and Canadian Phase III DREAM HF-1 trial evaluating a single catheter injection of MPC-150-IM into the damaged ventricular heart muscle of patients with...
BioCentury | Apr 10, 2017
Clinical News

Mesoblast's MPCs clear interim heart failure hurdle

Mesoblast Ltd. (ASX:MSB; NASDAQ:MESO) said an independent DMC recommended continuation of a Phase III trial of chronic heart failure (CHF) candidate MPC-150-IM following an interim futility analysis of an efficacy endpoint evaluating non-fatal cardiac events....
BioCentury | Feb 17, 2017
Targets & Mechanisms

Gilding the Goldfinch

...Metabolic Solutions Development Co. MSDC-0602 Mitochondrial target of thiazolidinedione (mTOT) modulator that targets mitochondrial pyruvate carrier 1 (MPC1; BRP44L...
BioCentury | Dec 30, 2016
Company News

Mesoblast, Mallinckrodt deal

Mallinckrodt acquired a 5% stake in Mesoblast and obtained exclusive negotiation rights to two cell therapy candidates to treat low back pain and graft-versus-host disease (GvHD). Mallinckrodt will invest A$29.6 million ($21.6 million) through the...
Items per page:
1 - 10 of 162